THE CARDIAC NATRIURETIC PEPTIDES (NP) atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) are polypeptide hormones with important modulator actions, notably in the regulation of extracellular fluid volume, vascular tone, and cardiovascular growth in both health and disease (reviewed in Ref. 33) . Clinically, an increase in NP circulating levels is a specific and sensitive biomarker of myocardial dysfunction (34, 57) . At the cell level, two mechanisms are involved in such an increase. One is neuroendocrine based, as affected by agonists known to signal through G q protein-coupled receptors such as the endothelin-1 (ET-1) receptor (3, 11, 14) , angiotensin II receptor (27, 53) , and others (18, 21, 42, 45, 52) . A second mechanism of secretion is based on stretch of atrial muscle [stretch-secretion coupling (25) ], which is associated with G i/o signaling (3). Stretch-secretion coupling is sensitive to pertussis toxin (PTX), a potent inhibitor of G i/o signaling (54) . However, PTX-treated atria respond unhindered to stimulation of ANF secretion by agonists such as ET-1 (3), indicating that neuroendocrine agonist-promoted ANF secretion and stretch-promoted secretion occur through independent pathways.
In the present investigations we examined the involvement of components of the classical G q signaling cascade in G i/omediated stretch-secretion coupling using a pharmacological approach. We demonstrate an unexpected involvement of phospholipase C (PLC) and protein kinase C (PKC) in a tonic inhibition of basal ANF secretion as well as in the maintenance of the integrity of stretch-stimulated ANF secretion. In contrast, the second messenger inositol 1,4,5-trisphosphate (IP 3 ) and its receptor (IP 3 R) are shown to have an involvement in stretch-secretion coupling rather than in the regulation of basal ANF secretion.
MATERIALS AND METHODS

Animals.
Male Sprague-Dawley rats were obtained from Charles River Laboratories (each 225-275 g) and maintained with standard rat chow and water ad libitum at the animal care facilities of the University of Ottawa Heart Institute until reaching experimental body weights of 300 -375 g (ϳ5-7 days). In a subset of experiments investigating the role of G s proteins, cholera toxin (CTX; prepared as described below) was administered 16 h prior to euthanization via intraperitoneal injection. The experimental protocol was carried out according to the Canadian Council on Animal Care Guide to the Care and Use of Experimental Animals following approval by the University of Ottawa Animal Care Committee.
Solutions and pharmacological agents. The perfusion medium used was a Krebs' Ringer bicarbonate buffer (KRBB) solution consisting of 78 mM NaCl, 4.7 mM KCl, 2.54 mM CaCl 2·H2O, 1.36 mM NaH2PO4·H2O, 1.16 mM MgCl2·H2O, 25.0 mM NaHCO3, 20 mM HEPES, 2.0 mM sodium glutamate, 4.0 mM sodium fumarate, 2.0 mM sodium lactate, 11.6 mM glucose, 2.16 mU/ml zinc insulin (Humulin R; Eli Lilly, Minneapolis, MN), amino acids and vitamins as in modified Eagle's medium (Gibco-Invitrogen), 0.04 g of biotin (Sigma), 0.001% (wt/vol) bovine serum albumin, 0.01% (wt/vol) gelatine, 100 U/ml penicillin G (Sigma-Aldrich), and 0.25 g/ml fungizone (Gibco-Invitrogen). The solution was brought to pH 7.4 by the addition of NaOH, filtered at 0.45 m, and stored at 4°C for Յ48 h.
Cholera toxin, a G␣ s inhibitor, was purchased from Sigma-Aldrich, reconstituted at 1.0 g of CTX/L MilliQ-H 2O, and diluted in phosphate-buffered saline to a dose of 100 ng/kg body wt in a 500-l injection volume. All other pharmacological agents were purchased from EMD Biosciences or Calbiochem and prepared immediately prior to use. Edelfosine, a PLC inhibitor, was reconstituted in ethanol (5 mg ET-18-OCH 3 in 1 ml of ethanol) and diluted to experimental concentrations with nonoxygenated, prewarmed KRBB immediately prior to use. U-73122, a PLC inhibitor, and U-73343, an inactive analog of U-73122, were reconstituted in DMSO (Sigma-Aldrich) and further diluted to experimental concentrations by addition to prewarmed nonoxygenated KRBB. 2-Aminoethoxydiphenyl borate (2-APB), an IP 3R inhibitor, was dissolved and diluted to required concentrations in KRBB. The PKC inhibitors calphostin C (100 g) and Gö-6976 (500 g) were reconstituted in 100 and 1,000 l of DMSO, respectively, and diluted to experimental concentrations with KRBB, as described above.
Isolated atrial perfusion preparation. The atrial preparation used for these experiments has been described previously (8) . Briefly, following decapitation the heart was removed and placed in KRBB. A cannula was inserted from the inferior vena cava through the right atrium and out through the superior vena cava such that a small opening in the cannula faced the interior of the right atrial chamber. Following ligation of the coronary sinus, the left atrium, aorta, and pulmonary vein as well as most of the ventricles were dissected away, thus isolating the right atrium. A heat-curved lipped cannula (PE-10) was inserted through the tricuspid valve. The atrial preparation was then placed in a tissue bath and was continuously bathed by circulating KRBB that was bubbled 95% carbon dioxide-5% oxygen gas. Flow of KRBB through the atrium was via the superior vena cava, through the right atrial chamber, and out through the tricuspid valve. The final perfusion rate through the atrium was maintained at 3 ml/min under all conditions. The perfusate was collected using a fraction collector (15 ml for 5-min time intervals). Samples were taken every 20 min for radioimmunoassay (RIA), frozen immediately, and stored at Ϫ20°C.
Intra-atrial pressure was recorded on a Narco Bio-Systems Narcotrace Physiograph via connection to a pressure transducer. Basal atrial pressure was set to 0.5 mmHg. For stretch experiments, intraatrial pressure was increased to 8 mmHg by raising the tip of the outflow cannula in relation to the level of the atrium and pressure transducer. For all perfusion experiments, an equilibration time of 1 h (represented as Ϫ60 to 0 min) was allowed prior to the addition of pharmacological agents. All pharmacological agents were administered to the perfusion medium via a syringe pump at a rate of 0.33 ml/min. Flow of the perfusion medium was adjusted to maintain the final atrial flow rate of 3 ml/min. At the end of each perfusion, the tissue was quickly taken down from the perfusion apparatus and the cannula removed. Atria were immediately dissected out, flashfrozen in liquid N 2, and stored at Ϫ80°C for future assays.
RIA. Standard competitive RIA was performed to quantify ANF according to a previously published protocol (43) .
IP 3 and quantification. IP3 was extracted and measured using a commercial radio receptor-binding kit (D-myo-inositol 1,4,5-triphosphate [ 3 H] Biotrak Assay System TRK1000; Amersham Biosciences) according to the manufacturer's instructions. Cryopreserved perfused atrial tissue was washed into a polycarbonate tube with extraction solution and blended with a Polytron homogenizer (3 ϫ 10 s, with 15 s of chilling on ice in between). The extraction solution consisted of 5% trichloroacetic acid, 5 mM EDTA, 10 mM LiCl, 0.321%, and ATP. Aqueous/organic phases were separated with saturated ether. A 10% NaHCO 3-10% NaOH solution was used for neutralization. The acidified homogenate was centrifuged at 2,000 g for 15 min at 4°C, and the supernatant was washed three times with ϳ10 volumes of water-saturated diethyl ether. The final aqueous phase was collected and neutralized to pH 7.5 using a Universal Indicator (Fluka/Riedel de Haën). Standards were prepared at concentrations of 0.19, 0.38, 0.76, 1.5, 3.1, 6.2, 12.5, and 25 pmol/tube. Radioactive signal from 3 Hlabeled IP3 was detected on a ␤-scintillation counter.
Statistical analysis. All values are reported as means Ϯ SE, with n representing the number of independent experiments under the indicated treatments. The trapezoidal rule was used to calculate the area under the curve (AUC) Ϯ SE. To determine statistical significance, each time point measured was compared and analyzed by unpaired Student's t-test. A value of P Յ 0.05 was considered significant.
RESULTS
Effect of PLC inhibition on basal ANF secretion.
Isolated spontaneously beating atria were perfused with either the PLC inhibitor edelfosine or various doses of U-73122 for a period of 360 and 120 min, respectively. Both edelfosine and U-73122 reatment resulted in significant augmentations of ANF secretion (Fig. 1, A and B) in the absence of stimuli. Increases in ANF secretion were seen after 20 (U-73122) or 40 min (edelfosine) of treatment initiation and were sustained until the end of the experimental period. The inactive analog U-73343 did not have a significant effect on secretion (Fig. 1C) . Based on these results, a dose of 5 M for both inhibitors was chosen for subsequent experiments. Since ANF secretion was maintained continuously for Յ360 min, subsequent perfusion experiments were performed for a shorter period of 240 min. Heart rate and pressure monitoring of the ex vivo preparation (data not shown) did not reveal any differences between basal and all pharmacologically treated groups.
Effect of PLC inhibition on stretch-secretion coupling of ANF. Stretch-stimulated secretion resulted in a characteristic burst of ANF release from the atrial preparation ( Fig. 2A) . In experiments where isolated perfused atria underwent either edelfosine or U-73122 pretreatment, this characteristic response to stretch was not observed. Instead, with these treatments, addition of a stretch stimulus obtained by increasing intra-atrial pressure from 0.5 to 8 mmHg dramatically decreased the stimulated ANF secretion initially induced by the PLC inhibitors toward untreated basal levels ( Fig. 2 , B and C).
Effect of IP 3 R inhibition on ANF secretion. PLC stimulation activates two signaling pathways through IP 3 , which binds to the IP 3 R and through diacylglycerol (DAG), which activates PKC (Fig. 7) . To determine the role of PLC signaling cascade components responsible for the striking sustained increase in ANF secretion observed upon inhibition of PLC, IP 3 R was inhibited using 2-APB. In contrast to PLC inhibition, no elevation of ANF basal secretion was observed with various concentrations of 2-APB treatment (Fig. 3A) . However, 2-APB at 50 M significantly attenuated stretch-secretion coupling such that the characteristic spike in ANF secretion had significantly lower amplitude than nontreated tissue and was not significantly different from baseline (Fig. 3B) .
Effect of combined PLC and IP 3 R inhibition on basal and stimulated ANF secretion. In the absence of stretch stimulus, the combined administration of the PLC inhibitor edelfosine (5 M) and the IP 3 R inhibitor 2-APB (50 M) did not result in any significant changes in ANF secretion from perfused isolated atria compared with baseline values (Fig. 4) . Furthermore, when the intra-atrial pressure was increased to 8 mmHg at 120 min of perfusion, no stretch-induced increase in ANF secretion was observed, demonstrating a blockade of the atrial stretch response similar to that observed with administration of 2-APB alone (Fig. 3B) .
Quantification of IP 3 levels in isolated perfused atria. Following the perfusion experiments, atrial IP 3 levels were assessed. The atria that were subjected to stretch contained 4.7-fold higher IP 3 content than those of baseline (P Ͻ 0.001; Fig. 5 ). IP 3 levels were increased with edelfosine treatment, whereas IP 3 levels in U-73122-and U-73343-treated atria were similar to baseline levels. Consistent with PLC inhibition of stretch-secretion coupling (Fig. 2) , both edelfosine and U-73122 blocked the stretch-induced increase in IP 3 formation, with levels significantly below that observed in stretchstimulated atria (P Ͻ 0.01; Fig. 5 ). Levels of IP 3 measured in atrial tissue that had been perfused with 2-APB were similar to baseline levels. In 2-APB-treated atrial tissue that had undergone stretch stimulation, IP 3 levels were increased compared with 2-APB alone but did not reach statistical significance (Fig. 5) . ). The effects of the PKC inhibitors on ANF secretion were not as potent and had a slower onset than those observed following PLC inhibition at maximally inhibitory doses (edelfosine vs. calphositin C, P ϭ 0.03) but were similarly sustained at the heightened level for the duration of the experimental period.
Effect of PKC inhibition
Effect of PKC inhibition on stretch-stimulated ANF secretion. In a manner reminiscent of the results obtained with the PLC inhibitor treatments, the addition of a stretch stimulus resulted in a decrease in ANF secretion from heightened levels to near-baseline levels in the Gö-6976-treated atria (Fig. 6D) .
Prior to stretch, calphostin C treatment resulted in a sustained increase in ANF secretion to ϳ500 pg/ml. However, although there was an immediate drop in ANF secretion with Gö-6976 treatment when stretch was applied, with calphostin C there was first an acute spike in secretion to ϳ800 pg/ml followed by a decrease in ANF levels, as observed similarly with Gö-6976 treatment. The reduction in ANF stretch-stimulated secretion in calphostin C-treated atria was not as pronounced compared with that observed in Gö-6976-treated atria.
DISCUSSION
In the present study, we demonstrate that both PLC and PKC inhibition dramatically increase basal ANF secretion and that the addition of atrial muscle stretch, a well-established stimulus for ANF secretion, reversed the observed augmentation to pretreatment (basal) secretion levels. In addition, we demonstrate that IP 3 R blockade results in the suppression of stretchsecretion coupling. An important physiological stimulus for ANF secretion is deemed to be the mechanical distension of the atrial wall caused by an increase in blood volume flowing into the atria (25) . This distension can be reproduced reliably in the ex vivo, spontaneously beating, isolated atrial perfusion preparation used in the present studies. This preparation has long-term stability, the perfusion fluid flows in a physiologically correct form (i.e., from the cava to the tricuspid valve), and the phenotype of the cardiomyocytes is maintained along with other tissue components as present in vivo. The latter, including the extracellular matrix, can be expected to take part in the observed increased in ANF secretion following stretch of the atrial wall. This model is preferred over in vitro systems that we have tried over the years, such as those using adult isolated atrial cardiomyocytes or newborn ventricular cardiomyocytes, because these tend to lose phenotype and sensitivity to secretion agonists when placed in culture. In addition, it is not possible to induce long-term stretch-induced secretion of ANF in isolated cardiomyocytes even when the cells are cultured on stretchable membranes (unpublished observations). A disadvantage of the ex vivo models is that some studies are best performed using isolated cells such as Ca 2ϩ loading because of the certainty of the cell type involved in uptake.
Previously, we have shown that stretch-induced ANF secretion, referred to as stretch-secretion coupling (3), is PTX sensitive, thus implicating the heterotrimeric G i/o proteins in this phenomenon. In addition to atrial muscle stretch, ANF secretion is known to be stimulated by a number of neurohumors that signal through G␣ q . These two secretory pathways are independent from each other based on the observations that PTX-treated atria continue to respond to ET-1 treatment (3) and that stretch-induced ANF secretion is further potentiated by the addition of ET-1 in the perfusion medium (30) . By both immunocytochemistry (3) and oligonucleotide microarray analysis (36), G␣ o -1 is very abundant in atrial cardiomyocytes. These findings suggests that ATP-sensitive K ϩ (K ATP ) channels might be involved in stretch-secretion coupling because they are known to couple to G o proteins (41, 62) , are stretchsensitive (56) , and have been associated with other secretory processes (4, 35, 48) . Indeed, sulfonylurea ligands and channel openers known to affect K ATP channel activity as well as pharmacological inhibition of TWIK-related K ϩ channel 1 and the Ca ϩ2 -activated intermediate conductance K ϩ channel all affected ANF secretion. Interestingly, in the heart the latter channel is present only in the atrial appendages, which is the anatomic location of most of the ANF-producing cardiomyocytes (36) .
Because pharmacological agents that may directly affect G␣ q function are not available, in the present investigations we used pharmacological agents known to affect the classical proximal downstream effectors of G q (Fig. 7) .
The present study clearly demonstrates a negative modulation of ANF secretion through the activity of PLC in that the inhibition of PLC by edelfosine or U-73122 enhances ANF secretion in a sustained manner. Edelfosine is a membraneactive alkyl-lysophospholipid that potently acts to inhibit phosphoinositide-specific PLC by disrupting the association of G␣ q with PLC (17, 47) . Because of the significant effects observed on ANF secretion by edelfosine, a second PLC inhibiting agent, U-73122, was utilized. In fact, U-73122 has been employed to specifically inhibit IP 3 and DAG production through the inactivation of PLC and has the advantage that a similarly structured inactive analog, U-73343 (6, 51), is available. Both edelfosine and U-73122 produced an increase in basal ANF secretion in contrast to the negative control U-73343, thus suggesting that basal ANF secretion is dependent on PLC.
Consistent with PLC inhibition, IP 3 levels were similar to baseline values following treatment with U-73122 even with stretch-stimulation, which is known to increase IP 3 levels and inositol turnover (58, 59 ). In addition, since the hydrolysis of phosphatidylinositol 4,5-bisphosphate generates both IP 3 and DAG, the results shown in Fig. 5 suggest that DAG is not produced in the presence of U-713122, and hence, the PKC system was not stimulated. The different IP 3 concentrations induced by edelfosine and U-73122 (Fig. 5 ) may be expected to lead to different ANF secretion rates. This appears to be the case as gleaned from the data in Fig. 2 . In edelfosine-treated atrial tissue without stretch, IP 3 levels were significantly elevated compared with baseline levels. This is an especially intriguing phenomenon not only because it is the first demonstration of an increase in basal ANF secretion under PLC inhibitory conditions but also because PLC is well known as the immediate effector of G␣ q , through which many ANF secretagogues are thought to signal (15) . Hence, the observed increase in basal ANF secretion following inhibition of PLC appears counterintuitive. However, this finding is consistent with the fact that Ca 2ϩ is a tonic inhibitor of basal ANF secretion, as we have described previously (25) , and is similar to the previously reported relationship between Ca 2ϩ and renin secretion from juxtaglomerular kidney cells, which, like atrial cardiomyocytes, are modified muscle cells. The present observations are the first to show that inhibition of PLC leads to interruption of the cascade that is known to promote Ca 2ϩ release from IP 3 -sensitive Ca 2ϩ stores and hence, characterize the intracellular Ca 2ϩ intracellular storage pool involved in ANF secretion that is otherwise difficult to define given the unusual relationships between Ca 2ϩ and ANF secretion. For example, high K ϩ depolarization, which increases ionized intracellular Ca 2ϩ though the opening of voltage-sensitive Ca 2ϩ channels and stops contraction in isolated atrial tissue, does not affect ANF secretion from atria, although in other tissues such maneuvering results in an increase in the secretion of neurotransmitters and hormones (12, 13, 25) .
Our findings would also suggest that stretch normalizes (decreases) basal ANF secretion in PLC-inhibited atria by the release of Ca 2ϩ from intracellular stores. From the mechanistic point of view, these findings arise from pharmacological blockade of signaling implicating PLC in ANF release and hence, support the involvement of G␣ q and the previously reported tonic inhibition of ANF secretion by Ca 2ϩ . This ion, however, is required for normal basal as well as stimulated release by agonists such as ET-1 (50) .
That stimulated ANF secretion is Ca 2ϩ dependent is suggested by the sensitivity of stretch-secretion coupling to ryanodine (25) . Although no significant effects were observed with the ryanodine receptor agonist suramin or with the ␤-adrenergic agonist carvedilol (unpublished observations), the dependence of stretch-secretion coupling on increases in intracellular Ca 2ϩ is further corroborated by the attenuation of stretchsecretion coupling by 2-APB in the present study.
Pharmacological blockade of the IP 3 R did not elicit an increase in basal ANF secretion, in contrast to what was observed under PLC and PKC upstream inhibition. It would thus appear that basal ANF secretion is dependent on PLC and PKC but independent of the IP 3 R. As we have shown previously, stretch-secretion coupling is a PTX-sensitive process (5), we tested whether the persistent activation of adenylyl cyclase by treatment of the atria with CTX, an activator of G␣ s (9) , modified ANF secretion. We found that CTX did not have a significant effect on average basal secretion over 100 min before stretch with or without CTX (187 Ϯ 18 vs. 199 Ϯ 40 pg·ml Ϫ1 ·min Ϫ1 , respectively, P Ͼ 0.05) or over 100 min of stretch-stimulated ANF secretion with or without CTX (237 Ϯ 30 vs. 310 Ϯ 65 pg·ml Ϫ1 ·min Ϫ1 , respectively, P Ͼ 0.05). However, these findings do not rule out participation of G␣ o1 or the ␤/␥-subunits (G i ␤␥) of the G␣ i ␤␥ heterotrimer. In fact, G␣ o1 does not mediate adenylyl cyclase inhibition (49, 60) , although its splice variant G␣ o2 is as potent as G␣ i in inhibiting adenylyl cyclase activity in vitro (19, 24) . A direct interaction and potent activation of the IP 3 R by G i ␤␥ subunits has been shown previously (16, 26, 44, 63) . This mechanism should be considered in G protein-dependent stimulated ANF secretion given that in the present study inhibition of the IP 3 R, using 2-APB-attenuated stretch-secretion coupling (Fig. 3) , still produced IP 3 levels above baseline (Fig. 5) , albeit just below statistical significance. It thus appears to be IP 3 R rather than IP 3 itself that may be involved in stretch-secretion coupling.
Activation of PKC by DAG would be expected to occur downstream of PLC, and like PLC inhibition in the present studies the inhibition of PKC by two specific inhibitors, calphostin C and Gö-6976, showed similarly enhanced and sustained basal ANF secretion levels.
Others have shown that PKC inhibition by staurosporine decreased ET-1-stimulated ANF secretion but did not affect basal ANF release (38, 55) . A likely explanation for the apparent inconsistency between the latter studies and our findings might lie in the choice of PKC inhibitor. Staurosporine, which prevents ATP binding to kinases, is known to be a nonspecific kinase inhibitor affecting the activity of a variety of cAMP-dependent, cGMP-dependent, and phospholipid dependent (PKC) protein kinases, tyrosine protein kinases, and calcium/calmodulin protein kinases (1, 20, 39) . A comprehensive quantitative analysis ranked staurosporine as the least selective inhibitor out of 178 kinase inhibitors tested (1), whereas calphostin C was found to specifically inhibit PKC (IC 50 ϭ 0.05 M) by interacting with its regulatory region, and only at higher doses (IC 50 Ͼ 50 M) does it slightly inhibit cAMP-dependent kinases and tyrosine kinases (23) .
The activation of PKC by phorbol esters has been shown to increase ANF secretion from whole hearts (40) . Nonetheless, it has also been demonstrated that PKC negatively regulates PLC␤ and subsequent phosphoinositide hydrolysis by way of negative feedback (10) . Thus, strong direct activation of PKC by phorbol esters may quickly result in an inactivation of PLC and subsequently lead to an elevation of secreted ANF levels, therefore suggesting that this increase in ANF secretion may be due to inactivation of PLC and not by activation of PKC.
Inhibition of PKC by calphostin C increased baseline ANF secretion. Application of the stretch stimulus further increased ANF secretion (Fig. 6) . By contrast, no further increase in ANF secretion with stretch stimulation was observed from atria treated with the PKC inhibitor Gö-6976. This may be related to PKC isoform specificity of the PKC inhibitors used (32) . Calphostin C inhibits all of the diacylglycerol-dependent PKC isoforms, whereas Gö-6976 inhibits only the PKC isoforms ␣, ␤1/2, and ␥ (31, 61). This suggests isoform specificity of PKC involvement in ANF secretion.
In general, PKC inhibition was less effective than PLC inhibition in affecting ANF secretion, hinting at the presence of compensatory or alternative signaling downstream of PLC.
In summary, the present study demonstrates three new aspects regarding ANF secretion: the heightened and sustained basal secretion of ANF with PLC and PKC inhibition, the prompt declivity of secretion returning to baseline levels with the addition of atrial stretch to treatments with PLC or PKC inhibitors, and the suppression of stretch-secretion coupling with IP 3 R blockade. These findings strongly implicate G q proteins and members of the PLC-signaling cascade in a unique type of regulation of ANF secretion and suggest crosstalk between G q and G i/o signaling as well as implications for Summary of pharmacological targets of agents used in the present work. Activation of G protein-coupled receptors (GPCR) coupled to G␣q recruits PLC, which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate IP3 and diacylglycerol (DAG). IP3 then stimulates Ca 2ϩ release from intracellular stores [e.g., sarcoplasmic reticulum (SR)] through IP3Rs, whereas DAG activates PKC. Inhibitors used in the present study are shown. Inhibition of PLC (edelfosine and U-73122) and PKC (calphostin C and Gö-6976) relieves a postulated tonic inhibition of basal ANF secretion. Gq signaling could have a potential role in stretch-secretion coupling through actions of IP3 and IP3R, which is also likely to be stimulated by G␣o or G␤␥ groups released from heterotrimeric Gi/o proteins (dashed arrow). Lack of observed ability of calphostin C to prevent an additional increase in ANF secretion following stretch stimulation also suggests a role of specific PKC isoforms not affected by Gö-6976 in stretch-secretion coupling. Depiction of storage and secretion of ANF within the cell derived from Ref. 37. isoform-specific PKC participation. The overall findings are depicted in Fig. 7 , where the classical constitutive, exocytotic, and constitutive-like release of ANF is shown. The latter type of release is the main vectorial transport pathway for stimulated ANF secretion, as demonstrated by previous investigations from this laboratory (37) .
The unique dependence of ANF secretion on G protein signaling suggests further inquiry into this aspect of atrial secretory function. 
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